Skip to main content

Table 1 The clinical baseline information of the IgA nephropathy group, serum control group and kidney control group

From: Role of abnormal glycosylated IgA1 and interstitial transformation of glomerular endothelial cells in the development and progression of IgA nephropathy

 

IgA nephropathy group

serum control group

kidney control group

Sex (Male/Female)

14/6

11/9

4/6

Age (year)

8.5(7.0,11.0)

9.5(9.0,13.0)

2.5(2.0,5.3)

urine protein (g/24 h)

1.2 ± 0.25

0

0

urine erythrocyte(/µL)

382.5(75.8,996.3)

0

0

SCr (µmol/L)

51.9 ± 18.4

43.9 ± 10.2

32.7 ± 13.8

eGFR (ml/min)

229.9 ± 81.3

132.8 ± 28.0

78.8 ± 19.8

SUA (µmol/L)

272.5 ± 73.4

262.6 ± 81.2

335.1 ± 147.2

BUN (mmol/L)

4.3 ± 1.4

4.6 ± 1.2

4.7 ± 1.3

TC (mmol/L)

4.6 ± 1.6

3.8 ± 0.8

/

TG (mmol/L)

1.2 ± 0.6

0.9 ± 0.4

/

HDL-C(mmol/L)

1.4 ± 0.2

1.4 ± 0.3

/

LDL-C(mmol/L)

2.8 ± 1.4

2.1 ± 0.7

/

Serum IgA (g/L)

2.5 ± 0.063

/

/

C3(g/L)

1.2 ± 0.2

/

/

systolic pressure(mmHg)

103(98.5,107.5)

/

/

diastolic pressure(mmHg)

65(60,65)

/

/

MEST score

M0/M1

8/12

/

/

S0/S1

7/13

/

/

T0/T1

13/7

/

/

E0/E1

20/0

/

/